In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

2018361 citationsJournal Articlegold Open Access

Authors

Julie Parmentier · AbbVie (United States)

J W Voss · AbbVie (United States)

Candace Graff · AbbVie (United States)

Annette Schwartz · AbbVie (United States)

M.A. Argiriadi · AbbVie (United States)

Michael Friedman · AbbVie (United States)

Heidi S. Camp ·

Abstract

The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.

Topics & Keywords

Cytokine Signaling Pathways and Interactions Rheumatoid Arthritis Research and Therapies Pharmacological Effects of Natural Compounds

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMC Rheumatology

Volume 2, Issue 1, pp. 23-23

DOI: 10.1186/s41927-018-0031-x

Field-Weighted Citation Impact: 10.87